Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection

– Collaboration is designed to improve analytical speed and accuracy of Freenome's blood-based cancer screening tests –  BRISBANE, Calif., Jan. 12, 2026 /PRNewswire/ -- Freenome today announced an initiative to advance its blood-based early cancer screening program by leveraging NVIDIA deep learning technology and expertise to improve the recognition of cancer-specific patterns in the blood at the disease's earliest stages. With NVIDIA accelerated computing, Freenome will scale up training of its proprietary cell-free DNA (cfDNA) fragment-level deep learning (FLDL) models, as well as build an open-source methylation foundational model. Catching cancer early has been shown to lead to better clinical outcomes, but detection is challenging because the early biological signals of cancer in the blood can be subtle and hard to identify. Freenome's multiomics platform profiles DNA methylation, RNA, protein and other analytes, and for each individual, generates billions of data points across different modalities. The use of AI/ML and deep learning is critical to determining which samples harbor cancer signals. For cfDNA, Freenome's FLDL model outperforms the state-of-the-art ML method and shows improved performance with increases in training data volume, as presented at the 2025 AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning.1 "NVIDIA's expertise in accelerated computing hardware and software has helped Freenome solve data loading and othe...